HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores

Direct acting antiviral treatment (DAA) has been the standard of care for hepatitis C virus (HCV) infection, but its long‐term benefits in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) improvement and hepatic fibrosis assessed by aspartate aminotransferase–to–platelet ratio ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Tung, Ma, Stephanie, Hu, Ke‐Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701463/
https://www.ncbi.nlm.nih.gov/pubmed/36221305
http://dx.doi.org/10.1002/hep4.2098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701463/
https://www.ncbi.nlm.nih.gov/pubmed/36221305
http://dx.doi.org/10.1002/hep4.2098

Ejemplares similares